Related Experiment Video
Updated: May 13, 2026

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
Published on: April 27, 2018
Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression
Rachana Patel1, Meiling Gao, Imran Ahmad
1The Beatson Institute for Cancer Research, Glasgow, United Kingdom.
Abstract:
Concurrent activation of RAS/ERK and PI3K/AKT pathways is implicated in prostate cancer progression. The negative regulators of these pathways, including sprouty2 (SPRY2), protein phosphatase 2A (PP2A), and phosphatase and tensin homolog (PTEN), are commonly inactivated in prostate cancer. The molecular basis of cooperation between these genetic alterations is unknown. Here, we show that SPRY2 deficiency alone triggers activation of AKT and ERK, but this is insufficient to drive tumorigenesis. In addition to AKT and ERK activation, SPRY2 loss also activates a PP2A-dependent tumor suppressor checkpoint. Mechanistically, the PP2A-mediated growth arrest depends on GSK3β and is ultimately mediated by nuclear PTEN. In murine prostate cancer models, Pten haploinsufficiency synergized with Spry2 deficiency to drive tumorigenesis, including metastasis. Together, these results show that loss of Pten cooperates with Spry2 deficiency by bypassing a novel tumor suppressor checkpoint. Furthermore, loss of SPRY2 expression correlates strongly with loss of PTEN and/or PP2A subunits in human prostate cancer. This underlines the cooperation between SPRY2 deficiency and PTEN or PP2A inactivation in promoting tumorigenesis. Overall, we propose SPRY2, PTEN, and PP2A status as an important determinant of prostate cancer progression. Characterization of this trio may facilitate patient stratification for targeted therapies and chemopreventive interventions.
Insights
Loss of SPRY2 in prostate cancer activates a tumor suppressor checkpoint, but PTEN loss cooperates with SPRY2 deficiency to drive tumor growth and metastasis.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Prostate cancer progression involves concurrent activation of RAS/ERK and PI3K/AKT pathways.
- Negative regulators like sprouty2 (SPRY2), protein phosphatase 2A (PP2A), and phosphatase and tensin homolog (PTEN) are frequently inactivated.
Purpose of the Study:
- To elucidate the molecular basis of cooperation between genetic alterations in SPRY2, PTEN, and PP2A in prostate cancer.
- To investigate the role of SPRY2 deficiency in tumor suppressor checkpoints and its interaction with PTEN loss.
Main Methods:
- Utilized murine prostate cancer models to study the synergistic effects of Spry2 and Pten deficiency.
- Analyzed the activation of AKT, ERK, PP2A, and GSK3β pathways in response to genetic alterations.
- Correlated SPRY2, PTEN, and PP2A expression levels in human prostate cancer samples.
Main Results:
- SPRY2 deficiency alone activates AKT and ERK but is insufficient for tumorigenesis, instead triggering a PP2A-dependent tumor suppressor checkpoint.
- PTEN haploinsufficiency synergizes with Spry2 deficiency in mouse models, driving prostate tumorigenesis and metastasis.
- Loss of SPRY2 expression strongly correlates with loss of PTEN and/or PP2A subunits in human prostate cancer.
Conclusions:
- Loss of PTEN cooperates with SPRY2 deficiency by bypassing a novel tumor suppressor checkpoint, promoting prostate cancer progression.
- The interplay between SPRY2, PTEN, and PP2A is a critical determinant of prostate cancer progression.
- Assessing the status of SPRY2, PTEN, and PP2A may aid in stratifying patients for targeted therapies and chemoprevention.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

